Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(3 sites)
China
Peking University Third Hospital, Beijing, Beijing Municipality Beijing Cancer Hospital, Beijing, Beijing Municipality Sun Yat-sen University Cancer Center, Guangzhou, Guangdong